The Startup That Didn't Have to Die
I once watched a brilliant MedTech startup die.
Not because their technology failed. It worked beautifully. Not because they ran out of ideas. They had too many.
They had 5 indications, 3 regulatory tracks, distributors in 4 countries, and a founding team of 6 people trying to do it all. By the time they realised they needed to focus, they had burned 18 months and $3M on the wrong priorities.
I have seen this pattern more times than I care to count.
Twenty years at a major MedTech multinational taught me that the products which scaled fastest were those that owned one indication, one specialty, one market completely — before expanding. Breadth is a Series C luxury. At Series A, it is a death sentence.
So I built a framework: 16 focus disciplines across 5 phases of the startup journey.
Start With Phase Zero: The 4A Access Lens
Before any of the 16 disciplines, there is a single diagnostic question that shapes everything downstream:
Which treatment access bottleneck are you actually solving?
The 4A Access Lens identifies four distinct types of access failure in healthcare:
| Access Bottleneck | What It Means |
|---|---|
| Availableness | The solution doesn't exist or can't physically reach the patient |
| Adoption | The solution exists but isn't being used by clinicians or patients |
| Awareness | People don't know the condition is treatable or that a solution exists |
| Affordability | The cost is prohibitive for patients, payers, or health systems |
This single diagnostic shapes your entire commercialisation strategy: your evidence requirements, your regulatory pathway, your pricing model, and your geography sequencing. Get this wrong, and every downstream decision is built on a flawed foundation.
The 5 Phases of MedTech Startup Strategy
Once you have identified your primary access bottleneck, the framework organises the startup journey into five sequential phases, each with its own set of focus disciplines:
Phase 1: Problem Validation
Focus areas: Indication, Specialty, Customer Focus
The first phase is about ruthless specificity. Which single indication will you own? Which clinical specialty will you serve? Who is your primary customer — the clinician, the hospital administrator, the payer, or the patient? Every answer narrows your focus, and that narrowing is a strategic asset, not a constraint.
Phase 2: Solution Design and IP
Focus areas: Differentiation, IP/FTO, Evidence Focus
With a validated problem, you build your solution with defensibility in mind. What makes your approach genuinely different? What intellectual property protects your position? What evidence will regulators, payers, and clinicians require before they trust your device?
Phase 3: Market Access Architecture
Focus areas: Regulatory, Geography, Pricing, Stakeholder Focus
This is where most MedTech startups either build a durable business or collapse under complexity. Regulatory strategy must align with your access bottleneck. Geography sequencing must reflect where your evidence is strongest and your pathway is clearest. Pricing must reflect the value you deliver to each stakeholder — not just what the market will bear.
Phase 4: Commercial Launch
Focus areas: Channel, Market Segment, Manufacturing Focus
A focused launch beats a broad one every time. Which channel gives you the fastest feedback loop? Which market segment will generate the reference cases that unlock the next segment? Can your manufacturing scale with demand without destroying quality or margin?
Phase 5: Scale and Strategic Positioning
Focus areas: Capital, Partnerships, Talent Focus
Scale is earned, not assumed. The capital you raise at this stage should accelerate a proven model, not fund the search for one. Partnerships should extend your reach into markets you have already validated. Talent should deepen capabilities you have already demonstrated.
Each Discipline Comes With Three Tools
For each of the 16 disciplines, the framework provides:
- The core question you must answer — a forcing function that prevents strategic drift
- The dilution trap that destroys value — the specific mistake most startups make at that stage
- A 60-second litmus test — a rapid diagnostic you can run with your founding team
The Phase Zero Litmus Test
Before you engage with any of the 16 disciplines, run this single test with your founding team:
Can every member of your founding team independently name the same primary access bottleneck your innovation addresses?
If the answers don't match, nothing downstream will either. Misalignment at Phase Zero is not a communication problem — it is a strategy problem. And no amount of execution excellence will compensate for a founding team that is solving different problems.
Why Focus Is Not the Enemy of Ambition
The most common objection to this framework is that focus limits opportunity. It does not. It sequences it.
The MedTech startups that achieve the greatest scale are almost always those that dominated a narrow space first. They built the clinical evidence, the regulatory precedent, the distribution relationships, and the reimbursement pathway for one indication in one market — and then used that foundation to expand with credibility and capital efficiency.
Breadth is a Series C luxury. At Series A, it is a death sentence.
The 4A Access Lens and the 16-discipline framework are not about limiting what your technology can do. They are about sequencing what your organisation should do — and when.
What's Next in This Series
This is the first in a series of 17 posts unpacking each discipline in detail. The next post focuses on Indication Focus — why one indication beats five, every time, and how to choose the right one.
If you are building a MedTech startup and want to apply the 4A Access Lens to your own situation, reach out to explore how Value Addition works with early-stage and growth-stage MedTech companies.
Alok Mishra has 20+ years of experience at a major MedTech multinational and advises MedTech startups on commercialisation strategy, market access, and strategic positioning.